Do patients with soft-tissue sarcomas treated with trabectedin have better clinical effects and a longer survival time than those treated with doxorubicin?

We thank for the comments from Wu et al. (1) on our research (2), comparison between trabectedin and doxorubicin in soft-tissue sarcomas. Reviewer Wu et al. said that in Table 1, we reported that 80 patients were included, which was inconsistent with the original study (3). In addition, Figure 6 showed the wrong data that the disease control rate of 54 of 75 patients in the experimental group and 41 of 39 patients in the control group lead to the inability to estimate the odds ratio (OR). We appreciate the suggestions. In Table 1, we listed the Hartmann's study (3) and we corrected the samples in Table 1 from (2). We now correct the Figure 6 of our research (2) since the mistake in typing the number (Figure 1).They also said that the authors conducted the sensitivity analysis only by omitting Schöffski et al.'s study (4) and did not further exclude the other included studies. Since the sensitivity was conducted by removing each study in term and selecting the most obvious change one, we only reported the result omitting Schöffski et al.'s study, which is the most obvious change article. Other included researches had smaller influence on the I 2 value than Schöffski et al.'s study.

show abstract

Comparison between trabectedin and doxorubicin in soft-tissue sarcomas-reply letter

Dang

Zhang

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Do patients with soft-tissue sarcomas treated with trabectedin have better clinical effects and a longer survival time than those treated with doxorubicin?

Cited by 1 publication

References 4 publications

Comparison between trabectedin and doxorubicin in soft-tissue sarcomas-reply letter

Comparison between trabectedin and doxorubicin in soft-tissue sarcomas-reply letter

Contact Info

Product

Resources

About